Palvella Therapeutics (NASDAQ: PVLA) net income
Palvella Therapeutics reported a net loss of $41.7m for fiscal 2025; in fiscal 2024 it reported a net loss of $17.4m. Earnings per share were −$3.71.
Palvella Therapeutics's best year of the last 10 was fiscal 2023. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$41.7m | — | — | −$3.71 |
| 2024 | −$17.4m | −193.3% | — | −$7.83 |
| 2023 | $18.7m | — | 43.7% | — |
| 2022 | −$33.3m | — | −128.5% | −$0.45 |
| 2021 | −$45.7m | — | −145.6% | −$0.71 |
| 2020 | −$37.2m | — | −127.0% | −$0.68 |
| 2019 | −$25.5m | — | −55.0% | — |
| 2018 | −$26.8m | — | −91.9% | — |
| 2017 | −$17.6m | — | −69.8% | — |
| 2016 | −$22.8m | — | −391.0% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Palvella Therapeutics net income compared with its sector
By net income for its latest fiscal year, Palvella Therapeutics ranks 243rd of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 241st | Elicio Therapeutics | −$39.6m | — |
| 242nd | OrthoPediatrics | −$39.6m | −16.8% |
| 243rd | Palvella Therapeutics | −$41.7m | — |
| 244th | Trevi Therapeutics | −$42.8m | — |
| 245th | 10x Genomics | −$43.5m | −6.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Palvella Therapeutics
- How much did Palvella Therapeutics earn in fiscal 2025?
- Palvella Therapeutics reported a net loss of $41.7m for fiscal 2025. In fiscal 2024 it reported a net loss of $17.4m.
- What are the earnings per share of Palvella Therapeutics?
- They were −$3.71 in fiscal 2025, compared with −$7.83 in fiscal 2024.
- What was the most profitable year for Palvella Therapeutics?
- Of its last 10 fiscal years, fiscal 2023, with $18.7m.
- Where does Palvella Therapeutics rank in its sector by net income?
- It ranks 243rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Palvella Therapeutics come from?
- From the annual report (Form 10-K) that Palvella Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Palvella Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Palvella Therapeutics: the Palvella Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.